Microbot Medical Inc. (NASDAQ: MBOT) recorded revenue during the first quarter of 2026 from its Limited Market Release of the LIBERTY Endovascular Robotic System, according to a company statement. The medical device company has since transitioned to a Full Market Release, with second-quarter revenue already exceeding first-quarter totals.

The company reports that hospitals in six states have adopted the LIBERTY system: Georgia, Florida, New York, Michigan, Massachusetts, and North Carolina. The number of accounts using the system has more than doubled since the end of the Limited Market Release period.

Boston became the first city where Microbot Medical has multiple accounts using the LIBERTY system. Two of the three sites that participated in the ACCESS-PVI pivotal clinical trial have adopted the technology.

The LIBERTY system has been used for various procedures, including what the company describes as robotic Prostatic Artery Embolization for Benign Prostatic Hyperplasia, robotic Genicular Artery Embolization for chronic knee pain treatment, and robotic Y-90 radioembolization mapping and treatment for liver cancer.

"Our success during the first quarter was demonstrated across multiple metrics, including the continued progress of the limited market release leading to us commence the Full Market Release," said Harel Gadot, Chairman, President and CEO.

The company launched new territories in the Midwest and Mid-Atlantic regions in early April, which have already secured accounts. Microbot Medical plans to expand its commercial strategy to additional U.S. regions in the second half of the year and prepare for international market entry.

Microbot Medical develops single-use, remotely operated robotic solutions for endovascular procedures. The information is based on a company press release statement.